“He who has health has hope; and he who has hope, has everything.” – Thomas Carlyle 

 

PNA Spotlight: Dr. Juan Fernandez-Miranda

This month the PNA Spotlight focuses on Dr. Juan Carlos Fernandez-Miranda, a Professor of Neurosurgery and the Surgical Director of Brain Tumor, Skull Base and Pituitary Centers at Stanford University. Dr. Fernandez-Miranda did a neurosurgery residency at La Paz University Hospital in Madrid, Spain. He completed a fellowship in microsurgical neuroanatomy at the University of Florida. He did clinical training in cerebrovascular surgery at the University of Virginia, and in endoscopic endonasal and open skull base surgery at University of Pittsburgh Medical Center (UPMC). He joined the faculty at Stanford earlier this year. He was kind enough to answer some questions from the PNA. His answers are below:

Read more

Count on your Xeris CareConnection™ Team for unparalleled Cushing’s Support

Cushing’s can be challenging, but there is support so patients can feel like themselves again. The main goal of treating Cushing’s is to get cortisol levels back to normal. This Pituitary Awareness Month, Xeris Pharmaceuticals® is highlighting the importance of one-on-one support for patients living with Cushing’s Syndrome and support for HCPs treating Cushing’s Syndrome.

Sign up to get dedicated support:

Patients: Sign up for support | Recorlev® (levoketoconazole)

HCP’s: Connect with Xeris support | RECORLEV® (levoketoconazole)

Have more questions? Call for more support at 1-844-444-RCLV (7258)

PNA Medical Corner: Cushing Disease and Double Pituitary Adenoma

This month in the PNA Medical Corner we focus on a study coauthored by two members of the PNA: Drs. Adriana Ioachimescu and Nathan Zwagerman. The research is a case study of a woman with two pituitary tumors.

Consecutive resections of double pituitary adenoma for resolution of Cushing disease: illustrative case

Read More

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles September 2025

News Articles September 2025

Community remembers young pituitary patient with a fundraiser, scholarship

An article in the Utica Observer Dispatch tells the story of a fifth grader named Olivia Sacco, who passed away last year from septo-optic dysplasia. Her condition meant she was born with an underdeveloped pituitary gland and had to be on hormone replacement for her entire young life. Recently the community held a lemonade stand to raise money for a scholarship in her honor. Read more here: https://www.uticaod.com/story/news/local/2025/08/26/olivias-memory-lives-on-in-hearts-of-community/85834655007/

 South Korean government cracks down on misuse of growth hormone

South Korea’s Ministry of Food and Drug Safety has launched an investigation into medical providers and pharmacies to crack down on misuse of growth hormones. Specifically, they are hoping to curb prescriptions of hormones and steroids given with promises to increase a child’s height or improve muscle mass. Read more: https://biz.chosun.com/en/en-science/2025/08/25/BMBNGXXUGRBJ3FK5KMDNMZEJMY/

Patient Story: 20-year-old pituitary tumor survivor races for a cure

A young woman in the UK is doing the Walk of Hope to raise money for brain tumor research. Esme Smith was first diagnosed at 11 years old with a golf ball-sized craniopharyngioma and successfully underwent surgery the following year. Read  more: https://www.inyourarea.co.uk/news/hampshire-brain-tumour-survivor-takes-on-25-5-mile-challenge-to-find-a-cure

Brain tumor detection: optimized deep learning

A study published on the website Nature.com looks at optimized deep learning for brain tumor detection.  The authors explore a hybrid approach with “VGG16, an attention mechanism, and optimized hyperparameters to classify brain tumors into different categories as glioma, meningioma, pituitary tumor, and no tumor”. Read more: https://www.nature.com/articles/s41598-025-04591-3#Sec18

Research Articles

September 2025 Research Articles

Pituitary Tumors

Long-term behaviour of non-functioning pituitary microadenomas: experience from a tertiary care centre in Romania.

Iftimie ME, Burcea IF, Dobre R, Pigni S, Prodam F, Poiană C.Front Endocrinol (Lausanne). 2025 Aug 11;16:1613239. doi: 10.3389/fendo.2025.1613239. eCollection 2025.

 

Clinical characteristics and surgical approach for pituitary granular cell tumors: a case series of six patients and literature review.

Liu J, Zhang W, Huang Q, Ye X, Huang G.Front Oncol. 2025 Aug 11;15:1490783. doi: 10.3389/fonc.2025.1490783. eCollection 2025.

 

Autoimmune thyroid disease and pituitary adenoma in a female patient with 18p deletion syndrome: a case report and review of the literature.

Ye J, Shu Y, Wang M, Luo H, Liang W, Lu Q, Mei W, Deng J.BMC Endocr Disord. 2025 Aug 25;25(1):199. doi: 10.1186/s12902-025-02017-9.

 

Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors.

Bouter J, Azemar N, Vela A, Dutheil P, Lesueur P, Stefan D, Reznik Y, Thariat J.Sci Rep. 2025 Aug 24;15(1):31085. doi: 10.1038/s41598-025-16960-z.

 

Pituitary Surgery

Alterations of Brain Structural and Functional Connectivity Networks and Its Correlations With Cognitive Function in Patients With Hypothalamic Syndrome Following Craniopharyngioma Resection.

Li S, Ma J, Tong Z, Jiang H, Li L, Zhang Y.Brain Behav. 2025 Aug;15(8):e70730. doi: 10.1002/brb3.70730.

 

Isolated syndrome of inappropriate antidiuresis (SIAD) after Transphenoidal surgery of a non-functioning pituitary adenoma: clinical case report.

Quilismal N, Risso M, Agüero P, Lima R, Garagorry F, Centurion D, Pineyro MM.Oxf Med Case Reports. 2025 Aug 25;2025(8):omaf152. doi: 10.1093/omcr/omaf152. eCollection 2025 Aug.

 

Diagnostics

A Web-Deployed, Explainable AI System for Comprehensive Brain Tumor Diagnosis.

Aksoy S, Demircioglu P, Bogrekci I.Neurol Int. 2025 Aug 4;17(8):121. doi: 10.3390/neurolint17080121.


Machine learning-based models and radiomics: can they be reliable predictors for meningioma recurrence? A systematic review and meta-analysis.

Niroomand B, Mohammadzadeh I, Hajikarimloo B, Habibi MA, Mohammadzadeh S, Bahri AM, Bagheri MH, Albakr A, Karmur BS, Borghei-Razavi H.Neurosurg Rev. 2025 Aug 27;48(1):623. doi: 10.1007/s10143-025-03744-2.


From Detection to Diagnosis: An Advanced Transfer Learning Pipeline Using YOLO11 with Morphological Post-Processing for Brain Tumor Analysis for MRI Images.

Chourib I.J Imaging. 2025 Aug 21;11(8):282. doi: 10.3390/jimaging11080282.

 

Hormonal Health
Oxytocin, Vasopressin and Stress: A Hormetic Perspective.

Nazarloo HP, Kingsbury MA, Lamont H, Dale CV, Nazarloo P, Davis JM, Porges EC, Cuffe SP, Carter CS.Curr Issues Mol Biol. 2025 Aug 7;47(8):632. doi: 10.3390/cimb47080632.

 

Acromegaly

Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy With a Linear Accelerator (LINAC) for Acromegaly Remission: Clinical Experience From a Tertiary Neurological Center in Latin America.

Santos-Santos RI, Flores-Vázquez JG, Rodriguez-Hernandez LA, Fuentes-Calvo I, Rodríguez-Hernández IA, Mateo Nouel EJ, Villanueva-Castro E, Muñuzuri-Camacho MA, Palacios-Rodríguez RA, Wong-Achi X, Villalobos-Díaz R, Moncada-Habib T, Moreno-Jiménez S, Gutierrez-Aceves GA, Portocarrero-Ortiz LA.Cureus. 2025 Jul 24;17(7):e88708. doi: 10.7759/cureus.88708. eCollection 2025 Jul.

Cushing’s

Relapse of Cyclic Cushing Syndrome With a 19-Year Remission: Potential Involvement of COVID-19 in the Relapse.

Takayama K, Mukai K, Motoda S, Ose N, Obata Y, Shimomura I.JCEM Case Rep. 2025 Aug 22;3(10):luaf189. doi: 10.1210/jcemcr/luaf189. eCollection 2025 Oct.

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.